optimisation of combination therapy for treatment of pseudomonas aeruginosa alex cochrane bristol...
TRANSCRIPT
Optimisation of Optimisation of combination therapy for combination therapy for
treatment of treatment of Pseudomonas Pseudomonas
aeruginosaaeruginosa
Alex CochraneAlex CochraneBristol Centre for Antimicrobial Research and Evaluation
University of Bristol
Why use combination Why use combination therapy?therapy?
Monotherapy or Combination Therapy?The Pseudomonas aeruginosa Conundrum
Kristi Traugott, Pharmacotherapy 2011
► Medline search 1950 to 2010Medline search 1950 to 2010 P. aeruginosaP. aeruginosa bacteraemia and pneumonia bacteraemia and pneumonia
► ConclusionsConclusions Is there clinically significant synergy?Is there clinically significant synergy?
► UnknownUnknown Is there clinically significant reduction in Is there clinically significant reduction in
resistance?resistance?► UnknownUnknown
Initial StudyInitial Study► AntimicrobialsAntimicrobials
Piperacillin TazobactamPiperacillin Tazobactam GentamicinGentamicin
► OrganismOrganism Bloodculture isolate of Bloodculture isolate of Pseudomonas aeruginosaPseudomonas aeruginosa MIC gentamicin = 2 (sensitive)MIC gentamicin = 2 (sensitive) MIC piperacillin tazobactam = 8 (sensitive)MIC piperacillin tazobactam = 8 (sensitive)
► MethodologyMethodology Kill curveKill curve Sampled at 0, 1,3,6,12,24,36 and 48 hours.Sampled at 0, 1,3,6,12,24,36 and 48 hours. Antibiotic concentrations chosen to reflect Antibiotic concentrations chosen to reflect
concentrations that would be found in serum concentrations that would be found in serum during a standard dosing regimenduring a standard dosing regimen
Antibiotic concentrations Antibiotic concentrations usedused
Gentamicin ConcentrationGentamicin Concentration15mg/l15mg/l 4.5mg/l4.5mg/l 0.5mg/l0.5mg/l 0.1250.125
mg/lmg/lnilnil
P/T
P/T
co
nce
ntra
tion
con
cen
tratio
n
196mg196mg/l/l
AA BB CC DD EE
28mg/l28mg/l FF GG HH II JJ
1mg/l1mg/l KK LL MM NN OO
nilnil PP QQ RR SS Growth Growth controlcontrol
ResultsResults
MonotherapyMonotherapy
Piperacillin tazobactam alone
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
Growth ControlPipTazo 196 Gentamicin 0PipTazo 28 Gentamicin 0PipTazo 1 Gentamicin 0
time (h)
log
cfu
/mL
Gentamicin alone
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 0 Gentamicin 15PipTazo 0 Gentamicin 4.5PipTazo 0 Gentamicin 0.5PipTazo 0 Gentamicin 0.125Growth Control
time (h)
log
cfu
/mL
ResultsResults
Combination therapyCombination therapy
Synergy: low concentration gentamicin and high concentration P/T
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 196 Gentamicin 0.5PipTazo 196 Gentamicin 0PipTazo 0 Gentamicin 0.5Growth Control
time (h)
log
cfu
/mL
Synergy: low concentration gentamicin and high concentration P/T
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 196 Gentamicin 0.5PipTazo 196 Gentamicin 0PipTazo 0 Gentamicin 0.5Growth Control
time (h)
log
cfu
/mL
Synergy average concentration PT with low concentration Gentamicin
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 28 Gentamicin 0.5PipTazo 28 Gentamicin 0PipTazo 0 Gentamicin 0.5Growth Control
time (h)
log
cfu
/mL
Synergy average concentration PT with low concentration Gentamicin
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 28 Gentamicin 0.5PipTazo 28 Gentamicin 0PipTazo 0 Gentamicin 0.5Growth Control
time (h)
log
cfu
/mL
Synergy low concentration P/T, low concentration Gentamicin
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 1 Gentamicin 0.5PipTazo 1 Gentamicin 0PipTazo 0 Gentamicin 0.5Growth Control
time (h)
log
cfu
/mL
Synergy: High concentration P/T and very low concentration Gentamicin
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 196 Gentamicin 0.125PipTazo 196 Gentamicin 0PipTazo 0 Gentamicin 0.125Growth Control
time (h)
log
cfu
/mL
Combinations for reduction of Combinations for reduction of development of resistance: 24 development of resistance: 24
hourshoursGentamicin ConcentrationGentamicin Concentration
15mg/l15mg/l 4.5mg/l4.5mg/l 0.5mg/l0.5mg/l 0.125m0.125mg/lg/l
nilnil
P/T
P/T
co
nce
ntra
tion
con
cen
tratio
n
196mg/196mg/ll
28mg/l28mg/l
1mg/l1mg/l
nilnil Growth Growth controlcontrol
Resistance at 4 X MIC Resistance at 32 X MIC
Resistance - SummaryResistance - Summary
►High level resistance to High level resistance to Piperacillin/Tazobactam developed Piperacillin/Tazobactam developed within 48 hours only in the absence of within 48 hours only in the absence of gentamicin.gentamicin.
► High level resistance to gentamicin High level resistance to gentamicin developed within 48 hours only in the developed within 48 hours only in the absence of Piperacillin/Tazobactamabsence of Piperacillin/Tazobactam
Next stepNext step
►Compare standard dosing and Compare standard dosing and continuous infusion schedules of P/T continuous infusion schedules of P/T alone or in combination with 24hrly alone or in combination with 24hrly and 8hrly dosing of gentamicin in an and 8hrly dosing of gentamicin in an in in vitrovitro dynamic model. dynamic model.
AcknowledgementsAcknowledgements
Alan Noel
Karen Bowker
Alasdair MacGowan
All staff at Bristol Centre for Antimicrobial Research and Evaluation
University of Bristol
Synergy average P/T, very low gentamicin
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 28 Gentamicin 0.125PipTazo 28 Gentamicin 0PipTazo 0 Gentamicin 0.125Growth Control
time (h)
log
cfu
/mL
Synergy low concentration PT, very low concentration Gentamicin
0 6 12 18 24 30 36 42 4810
100
1000
10000
100000
1000000
1.0×1007
1.0×1008
1.0×1009
1.0×1010
1.0×1011
PipTazo 1 Gentamicin 0.125PipTazo 1 Gentamicin 0PipTazo 0 Gentamicin 0.125Growth Control
time (h)
log
cfu
/mL
Combinations for reduction of Combinations for reduction of development of resistance: 48 development of resistance: 48
hourshoursGentamicin ConcentrationGentamicin Concentration
15mg/l15mg/l 4.5mg/l4.5mg/l 0.5mg/l0.5mg/l 0.125m0.125mg/lg/l
nilnil
P/T
P/T
co
nce
ntra
tion
con
cen
tratio
n
196mg/196mg/ll
28mg/l28mg/l
1mg/l1mg/l
nilnil Growth Growth controlcontrol
Resistance at 4 X MIC Resistance at 32 X MIC
Combinations for reduction of Combinations for reduction of development of resistance: 24 development of resistance: 24
hourshoursGentamicin ConcentrationGentamicin Concentration
15mg/l15mg/l 4.5mg/l4.5mg/l 0.5mg/l0.5mg/l 0.125m0.125mg/lg/l
nilnil
P/T
P/T
co
nce
ntra
tion
con
cen
tratio
n
196mg/196mg/ll
28mg/l28mg/l
1mg/l1mg/l
nilnil Growth Growth controlcontrol
Resistance at 4 X MIC Resistance at 32 X MIC